BioLineRx (BLRX) Research & Development (2010 - 2026)
BioLineRx (BLRX) reported Research & Development of -$2.94 million for the quarter ended Jun 30, 2026, compared with -$2.33 million a year earlier.
Powered by 
Analysis
BioLineRx (BLRX) Research & Development (2010 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, BioLineRx's Research & Development came in at -$9.62 million; for the year ended Dec 31, 2025, it was -$8.09 million.
- By year, Research & Development came in at -$9.15 million in the year ended Dec 31, 2024, -$12.52 million in the year ended Dec 31, 2023, -$17.63 million in the year ended Dec 31, 2022 and -$19.47 million in the year ended Dec 31, 2021.
- The figure for the quarter ended Jun 30, 2026 ranks as the lowest quarterly Research & Development since the quarter ended Dec 31, 2023.
- Per Business Quant data, the three quarters before the quarter ended Jun 30, 2026 came in at -$2.53 million (quarter ended Mar 31, 2026), -$2.43 million (quarter ended Dec 31, 2025) and -$1.72 million (quarter ended Sep 30, 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,146.94 Bn | 1,115.53 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 624.96 Bn | 543.49 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 510.15 Bn | 483.27 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 366.13 Bn | 320.51 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 297.75 Bn | 261.74 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.93 Bn | 235.62 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 236.51 Bn | 191.91 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 194.27 Bn | 168.47 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 171.74 Bn | 118.39 Bn | 10.94 Bn | 2.81 Bn |
| 10 | BioLineRx | 9.10 Mn | -67.42 Mn | 235,000.00 | 2.94 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.94 Mn |
| Mar 31, 2026 | -2.53 Mn |
| Dec 31, 2025 | 13.76 Mn |
| Sep 30, 2025 | -1.72 Mn |
| Jun 30, 2025 | 2.33 Mn |
| Mar 31, 2025 | -1.62 Mn |
| Dec 31, 2024 | 16.43 Mn |
| Sep 30, 2024 | -2.57 Mn |
| Jun 30, 2024 | 2.23 Mn |
| Mar 31, 2024 | -2.49 Mn |
| Dec 31, 2023 | 21.94 Mn |
| Sep 30, 2023 | -2.73 Mn |
| Jun 30, 2023 | 3.01 Mn |
| Mar 31, 2023 | -3.68 Mn |
| Dec 31, 2022 | 31.83 Mn |
| Sep 30, 2022 | -4.37 Mn |
| Jun 30, 2022 | 5.40 Mn |
| Mar 31, 2022 | -4.44 Mn |
| Dec 31, 2021 | 33.81 Mn |
| Sep 30, 2021 | -4.92 Mn |
API Access
BioLineRx Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=BLRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "BLRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=BLRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();